When basal insulin therapy in type 2 diabetes mellitus is not enough—what next?
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus (T2DM) is a progressive disease characterized by co‐existing insulin deficiency (relative) and insulin insensitivity. Both fasting and post‐prandial blood glucose are elevated, exposing the patient to acute and chronic complications due to micro‐ and macro‐vascular angiopathy. Improving glycaemic control has been demonstrated to lower the risk of these complications. Owing to the progressive nature of the disease, an evolving treatment strategy is necessary to maintain glycaemic control. Insulin therapy is required when dietary and lifestyle modifications combined with oral hypoglycaemic agents fail to provide adequate glycaemic control. Adding an optimized dose of basal insulin to the existing oral therapy is a simple and widely used method for initiating insulin therapy. However, despite an effective control of fasting hyperglycaemia, further intervention to control post‐prandial hyperglycaemia may become necessary to achieve HbA 1c targets. Strategies for the addition of prandial insulin include administering short‐acting (or rapid‐acting) insulin analogues before each meal or twice‐daily administration of pre‐mixed insulin. As a single large meal often contributes to the greatest part of daytime hyperglycaemia, an alternative strategy is emerging with the addition of a single injection of prandial insulin prior to the meal that induces the largest post‐prandial blood glucose excursion measured 2 h after the start of the meal. Over time, additional prandial boluses of insulin may be required to sustain daytime glycaemic control. This strategy offers a simple, stepwise approach to progress from basal insulin to a basal–bolus regimen. Studies are needed to validate this method and better define specific titration tactics. Copyright © 2007 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“0%, in part by reducing the increment of glucose after meals, and can lead to weight loss [37,38].”
BackgroundSelf-citationTominaga, M., Eguchi, H., Manaka, H., Igarashi, K., Kato, T., & Sekikawa, A. (1999) · Diabetes Care · doi:10.2337/diacare.22.6.920 · Cited by 1,165
Postprandial Hyperglycemia and Diabetes Complications
Ceriello, A. (2005) · Diabetes · doi:10.2337/diabetes.54.1.1 · Cited by 945
Petersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818 · cited 1×
“relatively peak-less effect in typical patients with T2DM [14,15].”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.
Polonsky, K. S., Given, B. D., Hirsch, L. J., Tillil, H., Shapiro, E. T., Beebe, C., Frank, B. H., Galloway, J. A., & Van Cauter, E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181903 · Cited by 567
The DECODE Study Group, & on behalf of the European Diabetes Epidemiology Group (2003) · Diabetes Care · doi:10.2337/diacare.26.3.688 · Cited by 516
Fasting and Postchallenge Glycemia and Cardiovascular Disease Risk
Meigs, J. B., Nathan, D. M., D’Agostino, R. B., & Wilson, P. W. F. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1845 · Cited by 509
Ahrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434 · cited 3×
“Similarly, results from the LANMET study [20]”
ResultNathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetologia · doi:10.1007/s00125-006-0316-2 · Cited by 420
Janka, H. U., Plewe, G., Riddle, M. C., Kliebe-Frisch, C., Schweitzer, M. A., & Yki-Järvinen, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.254 · Cited by 414 · cited 1×
“33 units/kg body weight (with insulin glargine) [19] to 0.”
BackgroundSelf-citationPostprandial Glucose Regulation and Diabetic Complications
Ceriello, A. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2090 · Cited by 362 · cited 1×
“However, physiological evidence suggests that rapid increments of glucose can have harmful effects on the vascular endothelium, perhaps mediated by an oxidative stress [27,28].”
BackgroundImprovement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes
Davies, M., Storms, F., Shutler, S., Bianchi-Biscay, M., Gomis, R., & for the AT.LANTUS Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1282 · Cited by 314 · cited 1×
“compared with physician-managed algorithms, suggesting effective self-management of basal insulin doses [17,20].”
ResultAssessing the potential for α-glucosidase inhibitors in prediabetic states
Holman, R. R. (1998) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(98)00038-2 · Cited by 197
Cited by
Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288
Self-citationRosenstock, J., Aronson, R., Grunberger, G., Hanefeld, M., Piatti, P., Serusclat, P., Cheng, X., Zhou, T., Niemoeller, E., Souhami, E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0917 · Cited by 272
Aroda, V. R., Rosenstock, J., Wysham, C., Unger, J., Bellido, D., González-Gálvez, G., Takami, A., Guo, H., Niemoeller, E., Souhami, E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1495 · Cited by 260
“Recommendations from the American Diabetes Association and the European Association for the Study of Diabetes suggest that if HbA1c targets are not achieved despite the addition of basal insulin in type 2 diabetes (1), treatment should be further advanced to combination injectable therapy with the progressive addition…”
BackgroundRiddle, M. C., Forst, T., Aronson, R., Sauque-Reyna, L., Souhami, E., Silvestre, L., Ping, L., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2462 · Cited by 253
Self-citationBowering, K., Case, C., Harvey, J., Reeves, M., Sampson, M., Strzinek, R., Bretler, D.-M., Bang, R. B., & Bode, B. W. (2017) · Diabetes Care · doi:10.2337/dc16-1770 · Cited by 119
“Black or African American 22 (6) 18 (5) 40 (6)”
Background
Metadata
- Authors
- Raccah, D., Bretzel, R. G., Owens, D., & Riddle, M.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2007-02-21
- Volume
- 23
- Issue
- 4
- Pages
- 257-264
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2127854940
- Cited by
- 112
- References
- 19
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.